AgomAb Therapeutics NV
NASDAQAGMB arrives at its September 17 earnings release after losing more than 22% in a single week — a steep move that frames the print as a critical test of confidence in its fibrotic disease pipeline. The price damage has been sharp. Shares closed at $12.28 on Monday, down nearly 6% on the day alone and down 7% over the past month. Against that backdrop, borrow availability has…
Snapshot as of 4 Oct 2026
AGMB arrives at its September 17 earnings release after losing more than 22% in a single week — a steep move that frames the print as a critical test of confidence in its fibrotic disease pipeline. The price damage has…
AGMB enters the week after earnings with an unusually clean analyst build and a short book that has been unwinding steadily — the tension is whether the Street's conviction translates into price recovery after a 7.5%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AGMB — free to start on ORTEX.
Sign up for free →Open AGMB on ORTEX